SciELO - Scientific Electronic Library Online

 
vol.55 número1A LOSS CAUSES A BREAKTHROUGHMEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Arquivos de Gastroenterologia

versión impresa ISSN 0004-2803versión On-line ISSN 1678-4219

Arq. Gastroenterol. vol.55 no.1 São Paulo enero/mar. 2018

http://dx.doi.org/10.1590/s0004-2803.201800000-02 

BRIEF COMMUNICATION

BIOIMPEDANCE: NEW APPROACH TO NON-INVASIVE DETECTION OF LIVER FIBROSIS - A PILOT STUDY

Bioimpedância: nova abordagem para detecção não invasiva da fibrose hepática - estudo piloto

Daniel IANNI FILHO 1  

Ilka de Fatima Santana Ferreira BOIN 2  

Ademar YAMANAKA 3  

1Universidade Estadual de Campinas (UNICAMP), Gastrocentro, Campinas, SP, Brasil.

2UNICAMP, Gastrocentro, Departamento de Transplante de Fígado, Campinas, SP, Brasil.

3UNICAMP, Departamento de Cirurgia, Campinas, SP, Brasil.

ABSTRACT

BACKGROUND:

Fibrosis are common structural hepatic change in patients with chronic hepatitis. Liver biopsy is the gold standard for determining the extent of liver fibrosis. Considering the technical difficulties and cost, improvements in non-invasive screening tools are greatly needed. Bioimpedance have been shown to be safe to evaluate tissue fibrosis.

OBJECTIVE:

To assess the utility of using monofrequential bipolar bioimpedance for the detection of severity of liver fibrosis consistent with chronic viral hepatitis C infections.

METHODS:

One hundred and ten patients were studied prospectively and formed two groups according to the lab tests results for the detection of HCV, ALT and AST: Group 1 Control (n=50 healthy patients with HCV negative and with ALT and AST values within the normal clinical range) and Group 2 Positive (n=60 patients positive for anti-HCV positive) which were biopsied. All patients underwent an examination with an Electro Sensor Complex, bioimpedance technology. To compare the groups 1 and 2, the ROC curves was used to determine the specificity and sensitivity of the bioimpedance to detect liver fibrosis. To identify liver fibrosis severity the Group 2 Positive was subdivided according to the liver biopsy results (Metavir fibrosis score) into: Sub Group 2A (F0-F1 n=25) - patients without or with minimal portal fibrosis and Sub Group 2B (F3-F4 n=20) patients with numerous septa/cirrhosis. A statistical analysis was conducted to analyze the bioimpedance data differences in delta of the conductance.

RESULTS:

From the comparison between Groups 1 and 2: 1) The delta value for conductance in the pathway representing the right foot-left hand minus left hand-right foot demonstrated a sensitivity of 85% and a specificity of 78% with a cutoff value ≤5 and P=0.0001. 2) For the comparison between Sub Group 2A (Metavir F0+F1) and Sub Group 2B (Metavir F3+F4), the neural network for the Electro Sensor Complex data demonstrated a sensitivity of 85% and a specificity of 72% with a cutoff probability >50% and P=0.001. AUCROC=0.81.

CONCLUSION:

Bioimpedance technology had good level sensitivity and acceptable specificity for detecting liver fibrosis using delta of the conductance. There is a potential for the use of bioimpedance technology as non-invasive approaches for screening of liver fibrosis.

HEADINGS: Liver cirrhosis, diagnosis; Biopsy; Fibrosis; Liver, pathology; Chronic hepatitis C; complications

RESUMO

CONTEXTO:

A fibrose é uma alteração hepática estrutural comum em pacientes com hepatite crônica. A biópsia hepática é o padrão ouro para determinar a extensão da fibrose hepática. Considerando as dificuldades técnicas e os custos, melhorias em ferramentas de rastreio não-invasivas são bastante necessárias. A tecnologia bioimpedância tem se mostrado ser segura para avaliar fibrose tecidual.

OBJETIVO:

Avaliar a utilidade do uso da bioimpedância bipolar para detectar a severidade da fibrose hepática compatível com a hepatite viral B e C.

MÉTODOS:

Cento e dez pacientes foram estudados, prospectivamente e dois grupos foram formados de acordo com os resultados dos testes laboratoriais para a detecção de HCV, ALT e AST: Grupo 1 Controle (n=50 pacientes saudáveis com HCV negativos e com valores de ALT e AST dentro do padrão de normalidade) e Grupo 2 Positivo (n=60 pacientes positivos para a infecção viral anti-VHC ou HBsAg positiva) que foram biopsiados. Todos os pacientes foram submetidos a um exame com o Electro Sensor Complex, que utiliza a bioimpedância bipolar. Para comparar os Grupos 1 e 2, a curva ROC foi utilizada para determinar a especificidade e sensibilidade da bioimpedância em detectar a fibrose hepática. Para identificar a severidade da fibrose hepática, o Grupo 2 Positivo foi subdividido de acordo com os resultados da biópsia (escore Metavir) em: Sub Grupo 2A (F0-F1 n=25 ) - pacientes sem ou com fibrose portal mínima e Sub Grupo 2B (F3-F4 n=20) pacientes com numerosos septos/cirrose. A análise estatística foi realizada para analisar as diferenças dos valores delta de condutância da bioimpedância.

RESULTADOS:

A comparação entre os Grupos 1 e 2 mostrou: 1) O valor delta de condutância na via do pé direito à mão esquerda menos o valor do delta da mão esquerda ao pé direito demonstrou uma sensibilidade de 85% e uma especificidade de 78%, com um valor de corte ≤5 e P=0,0001. 2). Na comparação entre o Sub Grupo 2A (Metavir F0+F1) e o Sub Grupo 2B (Metavir F3 + F4), a rede neural para os dados aferidos pelo Electro Sensor Complex demonstrou uma sensibilidade de 85% e uma especificidade de 72%, com um corte de probabilidade >50% P=0,001 e AUCROC=0,81.

CONCLUSÃO:

Bioimpedância apresentou boa sensibilidade e aceitável especificidade para a detecção da fibrose hepática utilizando o delta da condutância da bioimpedância. Existe um potencial para o uso da bioimpedância como abordagens não-invasivas para o rastreamento da fibrose hepática.

DESCRITORES: Cirrose hepática, diagnóstico; Biópsia; Fibrose; Fígado, patologia; Hepatite C crônica; complicações

INTRODUCTION

The risk factors for hepatic carcinogenesis in patients with chronic hepatitis have been extensively studied1 and liver fibrosis is known to be the most significant factor involved. Treatment decisions are based, in part, on the stage of liver fibrosis, which marks the progression to cirrhosis. The Metavir score is very useful scale to gauge the fibrosis severity.

The gold standard for determining the extent of fibrosis is liver biopsy2. However, this procedure carries a moderate risk for complications such as bleeding and a small risk of death2,3. Then there is interest in the development of non-invasive testing to determine the degree of hepatic fibrosis.

Bioimpedance is an electrical property of living tissues that has been applied in many biomedical settings, such as the quantification of brain edema in neurosurgery4 differentiating between cancerous pulmonary masses and pulmonary masses due to pneumonia5, in in prostate cancer6. However, bipolar bioimpedance has, so far as we are aware, not previously been applied in assessing liver fibrosis.

Bioimpedance uses a weak direct current (DC), voltage 1.28 V applied for two minutes and in bipolar mode. In living tissues, electrical current is normally limited in living tissue by highly insulating cell membranes, although measurements of this current can reflect acid levels in tissues and can therefore be used to detect hepatic alterations provoked by viral infection or abnormal architecture resulting from tissue fibrosis. Moreover, electrical current can be impeded differently, which enables the detection of differences between normal and fibrotic tissue.

The aim of this research was to assess the accuracy of non-invasive bipolar bioimpedance technology for the detection of liver fibrosis using physiological data intra and inter groups of the healthy and chronic viral hepatitis C patients

METHODS

This is a prospective study between January and December 2014. To assess the level of liver fibrosis comparing bipolar bioimpedance data from a Group 1 Control of healthy individuals, not biopsied, with the data and histopathology results of the Group 2 Positive patients with chronic hepatitis (virus C positive), biopsied and subdivided according to Metavir score into Sub Group 2A (F0-F1) patients without or with minimal portal fibrosis and Sub Group 2B (F3-F4),patients with numerous septa/cirrhosis. Approval number of the Ethical Committee - Faculty of Medical Science of Campinas (Unicamp) is CEP 542/2010.

As estimated by the sample calculation with significance level of 5% with 80% power, this study included 60 patients with chronic hepatitis, of both sexes that had all previously signed consent form and had positive serology for hepatitis C virus (anti-HCV positive). These exams were performed by health centers from cities within the greater metropolitan area of Campinas, São Paulo state, southeast of Brazil, whose patients were referred to Gastrocentro, State University of Campinas - Unicamp, for biopsies to be carried out in order to determine the stage of hepatitis virus C.

A Group 1 Control composed of 50 healthy patients, aged 18 to 57years, who were without symptoms, and who were not undergoing any treatments or liver biopsies and had negative lab tests for chronic hepatitis (virus C) were included only for the purpose of comparing bioelectric data.

Patients were excluded for the following reasons: 1) if they had a neurological disorder precluding the ability to sign a consent form; 2) if they had any constraints to use the bipolar bioimpedance, that such as presence of an external defibrillator, skin lesions likely to come into contact with the electrodes, excessive perspiration, cardiac pacemaker, electronic life support, any implanted electronic device, metallic pins or prostheses in digits or joints, pregnancy from the third trimester onwards, and absence of a limb; 3) if the Metavir fibrosis score is F2 only in specific analysis of liver fibrosis in the Group 2 Positive (chronic hepatitis group).

Bipolar bioimpedance measurements, were performed in all one hundred and ten patients of an average age of 39 (20-64), 57 men and 53 women, using the Electro Interstitial Scan-Galvanic Skin (EIS-GS) bioimpedance module with DC current, which uses the ES Complex (Electro Sensor Complex) system medical device (LD Technology Ltd, USA).7

The chronic hepatitis group immediately prior to the liver biopsy underwent a “blind” examination with electrical bioimpedance using a weak direct current (DC current), voltage 128 V which was applied for two minutes in bipolar mode performing measures of the electrical conductivity of different pathways in the body.

The parameter analyzed in the EIS-GS module was the delta of the electrical resistance values for the pathway value for the left foot to right hand (anode to cathode) minus the pathway value for the right hand to left foot (cathode to anode). The conductance measurement values are displayed in a scale from 0 to 100 for each pathway.

EIS and electrical conductance/chronoamperometry

With direct current, the plasma membrane acts as an insulator, and the current is therefore not able to penetrate the cell. Thus, most of the current flows around the cell in the interstitial fluid8 The analysis of the direct current at the cathode and anode in an electrolytic solution is performed at both the anode and cathode. For the analysis at the cathode, the electrochemical reaction is represented by the following:

2H2O + 2e= H2 (gas) + 2 OH-(base)

For the analysis at the anode, the electrochemical reaction for water is represented by the following:

2H2O = O2 (gas) + 4H+ + 4e- (acid)

Using as normal references the conductance values 9.2 µS (-4/19) of the Group 1 Control, was compared the groups 1 and 2 to determine the specificity and sensitivity of the bipolar bioimpedance data (delta of conductance) to detect liver fibrosis. The fibrosis severity was analyzed comparing the Sub Groups 2A and 2B. ES Complex Algorithm was made by Statistical Neural Network version 10. A part of developed algorithm was made in «C» language.

This was a triple blind study since the bioimpedance examination was done immediately before the liver biopsy without knowing the results. The liver biopsy was also performed without knowing the result of bioimpedance and liver fibrosis was graded by an independent pathologist using the Metavir classification did not know the result of bioimpedance.

RESULTS

Demographic data can be seen in TABLE 1. From the comparison between Groups 1 and 2:

TABLE 1: Demographic data for the 4 study groups: Group 1 Control, Group 2 Positive for hepatitis C virus-infected patients, Sub Group 2A-Metavir F0+F1, and Sub Group 2B-Metavir F3+F4 

Group 1 Group 2 Sub Group 2A Sub Group 2B ANOVA P-
Control Positive for HCV Metavir Metavir value
infection F0+F1 F3+F4
N 50 60 25 20
Age 32 (18-57) 46 (28-64) 44 (28-63) 49 (29-64) 0.05
Male/female ratio 0.56 0.66 0.68 0.75 0.05
ALT 15 (12-20) U/L 77 (15-260) U/L 70 (19-260) U/L 83 (15-185) U/L 0.001
AST 26 (15-38) 72 (16-271) 44 (27-78) 75.6 (16-271) 0.001
HCV No 60 25 20 Ns
Delta conductivity 9.2 (-4/19) 1.31 (-6/23) 2.75 (-6/12) 0.62 (-10/23) 0.001

The delta value for conductance in the pathway representing the right foot-left hand minus left hand-right foot demonstrated a sensitivity of 85% and a specificity of 78% with a cutoff value ≤5 and P=0.0001 (FIGURE 1).

FIGURE 1: Delta value of the conductance. The ROC curve for the Delta value of the conductance in the pathway of the right foot-left hand minus left hand-right foot for the comparison between Group 1 Control (virus-negative and within the normal range of ALT/AST levels) and Group 2 Positive (virus-positive and/or high levels ALT/AST). 

From the comparison between Sub Group 2A (Metavir F0+F1) and Sub Group 2B (Metavir F3+F4) the Receiver Operating Characteristic curve (ROC curve) neural network for the ES Complex data demonstrated a sensitivity of 85% and a specificity of 72% with a cutoff probability >50% and P=0.001 (FIGURE 2). The area under the ROC curve (AUROC) is 0.81.

FIGURE 2: The neural network. The ROC curve of the neural network for the ES Complex data comparing the Sub Group 2A (Metavir score F0+F1) and Sub Group 2B (Metavir score F3+F4). 

DISCUSSION

Chronic hepatitis is often closely associated with hepatic fibrosis. The response to injury consists of local inflammation followed by the recruitment and local proliferation of myofibroblast-like cells and the excessive deposition of the extracellular matrix. Therefore, within the past 20 years, hepatic fibrosis has become a common and difficult clinical challenge for gastroenterologists worldwide9.

Progressive degrees of fibrosis, and ultimately cirrhosis, are reflected in alterations in blood levels of various biomarkers, and the knowledge of such alterations has led to the development of predictive models based on clinically determined algorithms that utilize the levels of selected markers9,10.

One such model, the Hepascore, is based on the serum levels of α2-macroglobulin, hyaluronic acid, gammaglutamyltransferase (GGT), and total bilirubin in addition to age and sex. In one study, a Hepascore ≥0.5 (possible range, 0-1.0) demonstrated a sensitivity of 63% and a specificity of 89% for the presence of significant fibrosis (Metavir score ≥F2), whereas a Hepascore <0.5 demonstrated a sensitivity of 88% and a specificity of 74% for excluding a diagnosis of advanced fibrosis9.

Another useful model is the non-alcoholic fatty liver disease (NAFLD) fibrosis score that based on age, hyperglycemia, body mass index, platelet count, albumin, and AST/ALT ratio. In the validation study demonstrates good accuracy in to predict presence or absence of advanced fibrosis with an area under the ROC curve of 0.82, sensitivity of 82% and specificity of 88%11.

Ultrasonic transient elastography or FibroScan (Echosens, Paris, France), is a current approach for the non-invasive evaluation of liver fibrosis and has been shown to be an accurate predictor of histological fibrosis in patients with chronic hepatitis C. The best results with FibroScan is when the patient has higher level of fibrosis with AUROC ranging from 0.79 to 0.88 for F > or = 2 and 0.95 to 0.99 for F=4), and these new trends12,13.

In the present study, using delta of the electrical resistance values the comparison between patient from the Sub Group 2A (Metavir F0+F1) and Sub Group 2B (Metavir F3+F4) demonstrated good sensitivity (85%) and specificity (72%) to differentiation in liver fibrosis severity. The theoretical explanation is that the electrical weak DC current used in bipolar bioimpedance can be impeded differently, which enables the detection of differences between normal and fibrotic tissue.

It is not possible to discuss this result with other researchers because this is a pioneer study in liver. Prostatic research using bioimpedance offers the same explanation to understand how it could identify the variation in tissue architecture between different prostatic tissue types. This prompted, Halter RJ6 and de Abreu DS14,15 to suggest using the electrical properties of the prostate as a means to distinguish cancerous from non-cancerous tissue.

Bioimpedance is largely a function of a tissue’s cellular morphology and the ionic concentrations of the tissue’s intra- and extra-cellular fluids. Electrical current is normally limited in living tissue by highly insulating cell membranes, although measurements of this current can reflect acid levels in tissues. The second explanation for why bioimpedance is increased in hepatic fibrosis may be related to the fact that fibrotic tissue prevents the flow of the current because current flow decreases as resistance increases. A decrease in bioimpedance conductivity value (cutoff <5) is inversely proportional to the electrochemical reaction at the anode and can therefore be used to indicate an acidic tissue environment. In addition, this acidic tissue environment is likely related to tissue damage provoked by HCV infection7.

Hence, the bipolar bioimpedance used in ES Complex equipment is a tool easy to administer, non-invasive, and has a high sensitivity and specificity would be advantageous and a great improvement for the screenings to detect liver fibrosis in asymptomatic chronic hepatitis C virus infection but not for primary diagnostic use. The value of such a tool would increase if non-clinical personnel, who assist the doctors, could also use it.

This study has certain limitations, such as the sample size and the exclusion of 19 patients with positive Metavir score F2 (portal fibrosis with few septa) although one of the challenges of the liver fibrosis evaluation method is to identify the Metavir F2.

But the purpose of this pilot study that could not draw conclusive results since it is not a validation study. The intention is to present preliminary findings and to evaluate the potential of the use of bioimpedance as a supporting parameter that in the future can be included to the currently methods of the liver fibrosis identification may be to increase yours theirs sensitivity and specificity. Thus, bioimpedance further studies with a larger patient population and the use of multifrequential tetrapolar bioimpedance may provide more information not only on the interstitium but also on the intracellular environment thus contributed to the increased accuracy of the clinicians detect chronic liver fibrosis during screening procedures.

CONCLUSION

The bioimpedance demonstrate good to high levels of sensitivity and specificity to identify structural liver alterations like liver fibrosis severity consistent with chronic viral hepatitis C infections showing that there is a potential for the use of bioimpedance lie a non-invasive technology in the approaches for low-cost and rapid screening of liver fibrosis.

REFERENCES

1. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 1996;78:977-85. [ Links ]

2. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-71. [ Links ]

3. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:62S-5S. [ Links ]

4. Ko HW, Smith DG, Skura JP. In vitro measurements of brain edema with the magnetic bio-impedance method. IEEE, Engineering in Medicine and Biology Conference, Amsterdam, Netherlands, 1996. [ Links ]

5. Kimura S, Morimoto T, Uyama T, Monden Y, Kinouchi Y, Iritani T. Application of electrical impedance analysis for diagnosis of a pulmonary mass. Chest. 1994;105:1679-82. [ Links ]

6. Halter RJ, Hartov A, Paulsen KD, Schned A, Heaney J. Genetic and least squares algorithms for estimating spectral EIS parameters of prostatic tissues. Physiol Meas. 2008;29:111-23. [ Links ]

7. Maarek A. Electro interstitial scan system: assessment of 10 years of research and development. Medical Devices: Evidence and Research. Med Devices (Auckl). 2012;5:23-30. [ Links ]

8. Lewis JE, Tannenbaum SL, Gao J, Melillo AB, Long EG, Alonso Y, et al. Comparing the accuracy of ES-BC, EIS-GS, and ES Oxi on body composition, autonomic nervous system activity, and cardiac output to standardized assessments. Med Devices (Auckl) . 2011;4:169-77. [ Links ]

9. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1876-3. [ Links ]

10. Gish RG. Early detection of hepatocellular carcinoma through surveillance using biomarkers. Gastroenterol Hepatol (NY). 2014,10:121-3. [ Links ]

11. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54. [ Links ]

12. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705-13. [ Links ]

13. Calvaruso V, Cammá C, Di Marco V, Maimone S, Bronte F, Enea M, et al. Fibrosis staging in chronic hepatitis C analysis of discordance between transient elastography and liver biopsy. J Viral Hepat. 2010,17:469-74. [ Links ]

14. de Abreu DS. Bioimpedance and chronoamperometry as an adjunct to prostate-specific antigen screening for prostate cancer. Cancer Manag Research. 2011;3:109-16. [ Links ]

15. Lee BR, Roberts WW, Smith DG, Ko HW, Epstein JI, Lecksell K, Partin AW. Bioimpedance: novel use of a minimally invasive technique for cancer localization in the intact prostate. Prostate. 1999;39:213-8. [ Links ]

Disclosure of funding: no funding received

Recibido: 19 de Abril de 2017; Aprobado: 05 de Octubre de 2017

Correspondence: Daniel Ianni Filho. Universidade Estadual de Campinas (UNICAMP), Gastrocentro. Cidade Universitária Zeferino Vaz - Barão Geraldo - CEP: 13083-970, Campinas, SP, Brasil. E-mail: recadodaniel@terra.com.br

Declared conflict of interest of all authors: none

Authors’ contributions: Ianni Filho D: wrote the manuscript. Boin IFSF: reviewed the manuscript. Yamanaka A: participated in the sequence alignment.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License